Indian Council of Medical Research (ICMR) has invited Expression of Interest (EoI) from eligible organizations, companies, and manufacturers for developing real-time multiplex molecular diagnostic assays detecting priority pathogens causing critical infectious syndromes in India.
“ICMR invites this Expression of Interest (EoI) from applicants for the development of syndrome-specific multiplex real-time molecular diagnostic assays targeting Priority 1 pathogens causing these infectious syndromes. ICMR is lawfully entitled to enter into any form of exclusive/non exclusive agreements with eligible indigenous manufacturers having R&D facility / indigenous manufacturer working in collaboration with academia / academic facility with collaborative industry partner, hereinafter referred to as the “Applicant”, through a defined agreement for “Development of Real Time Multiplex Molecular Diagnostic Assays Detecting Priority Pathogens” with GMP certification,” ICMR said.
ICMR will facilitate the process of GMP-certified “Product” development till TRL-6 (Test License), followed by “Product” Performance Evaluation (TRL-7) for CDSCO approval.
ICMR will provide financial assistance to the applicant for product development through a milestone-based approach till “Test License” is obtained (TRL-6), unless otherwise specified. ii.
ICMR will provide overarching technical support in product development and will also facilitate its performance evaluation (TRL-7) for CDSCO approval (TRL-8), if required, as per the terms & conditions of the Agreement.
MB Bureau
